Trials / Completed
CompletedNCT05047458
A Study of Single-dose ALXN2050 in Healthy Adults
A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 25 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This was a phase 1, first-in-human, single-center, randomized, double-blind (participants and investigator blind, sponsor open) placebo-controlled, single-ascending dose study of ACH-0145228 (ALXN2050) conducted in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN2050 | Powder-in-capsule (PIC). |
| DRUG | Placebo | PIC. |
Timeline
- Start date
- 2017-11-28
- Primary completion
- 2018-04-13
- Completion
- 2018-04-13
- First posted
- 2021-09-17
- Last updated
- 2021-09-17
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT05047458. Inclusion in this directory is not an endorsement.